Vitronectin receptor antagonist pharmaceuticals

Details Vitronectin receptor antagonist pharmaceuticals Vitronectin receptor antagonist pharmaceuticals

2008-01-22

2008-01-22

Balasubramanian, Venkataraman (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S362100, C548S364400, C540S469000, C524S008000, C524S018000, C524S183000, C424S001650, C424S001810, C534S014000

Reexamination Certificate

active

07321045

ABSTRACT:
The present invention describes novel compounds of the formula:in-line-formulae description="In-line Formulae" end="lead"?(Q)d-Ln-Ch,in-line-formulae description="In-line Formulae" end="tail"?useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

REFERENCES:
patent: 4248802 (1981-02-01), Kuntz
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4536387 (1985-08-01), Sakamoto et al.
patent: 4859777 (1989-08-01), Toner
patent: 4988827 (1991-01-01), Bergstein et al.
patent: 5021236 (1991-06-01), Gries et al.
patent: 5064956 (1991-11-01), Kruper et al.
patent: 5087440 (1992-02-01), Cacheris et al.
patent: 5155215 (1992-10-01), Ranney
patent: 5183900 (1993-02-01), Galardy et al.
patent: 5189178 (1993-02-01), Galardy et al.
patent: 5268384 (1993-12-01), Galardy et al.
patent: 5281704 (1994-01-01), Love et al.
patent: 5342757 (1994-08-01), Garin-Chesa et al.
patent: 5350837 (1994-09-01), Bridger et al.
patent: 5376356 (1994-12-01), Morgan, Jr.
patent: 5382654 (1995-01-01), Lyle et al.
patent: 5395609 (1995-03-01), Stuttle
patent: 5403713 (1995-04-01), Bevilacqua et al.
patent: 5412148 (1995-05-01), Keana
patent: 5417959 (1995-05-01), Wallace
patent: 5520904 (1996-05-01), Nosco et al.
patent: 5556939 (1996-09-01), Flanagan et al.
patent: 5567411 (1996-10-01), Keana et al.
patent: 5650134 (1997-07-01), Albert et al.
patent: 5659013 (1997-08-01), Senger et al.
patent: 5659041 (1997-08-01), Pollak et al.
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5679810 (1997-10-01), Love et al.
patent: 5696147 (1997-12-01), Galardy et al.
patent: 5739789 (1998-04-01), Kronhamn
patent: 5744120 (1998-04-01), Edwards et al.
patent: 5750088 (1998-05-01), Sworin et al.
patent: 5760028 (1998-06-01), Jadhav et al.
patent: 5760191 (1998-06-01), Snow et al.
patent: 5766591 (1998-06-01), Brooks et al.
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5801228 (1998-09-01), Hollister et al.
patent: 5804161 (1998-09-01), Long et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5863538 (1999-01-01), Thorpe et al.
patent: 6040311 (2000-03-01), Duggan et al.
patent: 6051207 (2000-04-01), Kleveness et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6056973 (2000-05-01), Allen et al.
patent: 6254852 (2001-07-01), Glajch et al.
patent: 6322770 (2001-11-01), Rajopadhye et al.
patent: 5 314 694 (1994-07-01), None
patent: 2 113 245 (1988-06-01), None
patent: 2 039 259 (1991-10-01), None
patent: 2 156 620 (1994-10-01), None
patent: 2 232 315 (1997-04-01), None
patent: 4 311 023 (1994-10-01), None
patent: 19 536 781 (1997-03-01), None
patent: 19 536 785 (1997-03-01), None
patent: 19 725 368 (1998-12-01), None
patent: 0 095 906 (1983-12-01), None
patent: 0 107 734 (1987-07-01), None
patent: 0 359 347 (1990-03-01), None
patent: 0 436 005 (1991-10-01), None
patent: 0 606 683 (1994-07-01), None
patent: 0 727 225 (1996-08-01), None
patent: 0 819 431 (1998-01-01), None
patent: WO 81/01145 (1981-04-01), None
patent: WO 90/03801 (1990-04-01), None
patent: WO 90/05539 (1990-05-01), None
patent: WO 90/12585 (1990-11-01), None
patent: WO 90/13300 (1990-11-01), None
patent: WO 91/01144 (1991-02-01), None
patent: WO 91/14460 (1991-10-01), None
patent: WO 91/15244 (1991-10-01), None
patent: WO 92/12729 (1992-08-01), None
patent: WO 92/17215 (1992-10-01), None
patent: WO 92/19646 (1992-11-01), None
patent: WO 93/08210 (1993-04-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 94/05328 (1994-04-01), None
patent: WO 94/11499 (1994-05-01), None
patent: WO 94/22497 (1994-10-01), None
patent: WO 95/25543 (1995-09-01), None
patent: WO 96/00574 (1996-01-01), None
patent: WO 96/01653 (1996-01-01), None
patent: WO 96/31243 (1996-10-01), None
patent: WO 96/41803 (1996-12-01), None
patent: WO 97/08145 (1997-03-01), None
patent: WO 97/16474 (1997-05-01), None
patent: WO 97/18207 (1997-05-01), None
patent: WO 97/23480 (1997-07-01), None
patent: WO 93/23074 (1997-09-01), None
patent: WO 98/14220 (1998-04-01), None
patent: WO 98/16256 (1998-04-01), None
patent: WO 98/47541 (1998-10-01), None
patent: WO 99/06049 (1999-02-01), None
patent: WO 99/06347 (1999-02-01), None
patent: WO 99/13329 (1999-03-01), None
patent: WO 99/40947 (1999-08-01), None
patent: WO 99/58162 (1999-11-01), None
patent: WO 00/18439 (2000-04-01), None
patent: WO 00/35488 (2000-06-01), None
Wolft Manfréd E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
Abstract,Nucl. Med. Proceeding of the 42ndAnnual Meeting,1995, 36(5), No. 287, 71P.
Baker, et al.,Life Sci.,1991, 49, 1583-1591.
Batt, et al., Abstracts of Papers American Chemical Society, 1998, 216(1-3), p. MEDI 66.
Batt, et al.,J. Med. Chem.,2000, 43, 41-58.
Bevilacqua, et al.,Proc. Natl. Acad Sci.,1987, 84, 9238-9242.
Borrows, et al.,Proc. Nat. Acad. Sci. USA,1993, 90, 8996-9000.
Bousquet, et al.,Radiology,1988, 166, 693.
Brechbiel, M., et al.,Bioconjugate Chem.,1991, 2, 187.
Brechbiel, M., et al.,J. Chem. Soc. Perkin Trans.,1992, 1, 1175.
Brinkley, M.,Bioconjugate Chem.,1992, 3(1).
Burrows, F.J., et al.,Cancer Res.,1992, 52, 5954-5962.
Cheresh, et al.,Science,1995, 270, 1500-1502.
Clauss, et al.,J. of Biological Chem.,1990, 265(12), 7078-7083.
Clin. Can. Res.,1995, 1, 1623-1634.
The PCT International Search Report dated Jul. 26, 2002 (PCT/US01/19794).
CRC Handbook of Chemistry and Physics, 65thEd.,CRS Press,Boca Raton, FL., 1984.
DeGrado, et al.,J. Org. Chem.,1980, 45, 1295.
DeNardo, et al.,Cancer Biother.&Radioph.,2000, 15(1), 71-79.
Denekamp, J., et al.,Br. J. Cancer,1982, 45, 136-139.
Denekamp, J., et al., 1982,Br. J. Cancer,46, 711-720.
Denekamp, J.,Acta Radiologica Oncology,1984, 23 Fas. 4, 217-225.
Denekamp, J.,Cancer Meta. Rev.,1990, 9, 267-282.
Deshpande, S., et al.,J. Nucl. Med.,1990, 31, 473.
DiZio, et al.,Bioconjugate Chem.,1991, 2, 353-366.
Dvorak, et al.,Cancer Cells,1991, 3, 77-85.
Folkman, J.,Nature Medicine,1995, 1, 27-31.
Ghose, et al.,Meth. Enzymology,1983, 93, 280-333.
Greene, et al., “Protective groups in organic synthesis,”John Wiley&Sons,New York, 1991.
Hagemeier, H.-H., et al.,Int. J. Cancer,1986, 38, 481-488.
Haubner,V313 Nuclear-Medizin,1997.
Henry, T., et al.,J. Amer. College Cardiology,1998, 31, 65A.
Horton, et al.,Int. J. Biochem. Cell. Biol.,1997, 29(5), 721-725.
Hu, et al.,Oncology Res.,1994, 6(7), 321-327.
J. Org. Chem.,1996, 61, 903-908.
Kennel, et al.,Nuclear Med.&Biol.,1998, 25, 241-246.
Kerr, et al.,Anticancer Res.,1999, 19(2A), 958-968.
Krenning, et al.,Eur. J. Nucl. Med.,1993, 20, 716-731.
Krenning, et al.,Digestion,1996, 57, 57-61.
Liebigs,Ann. Chem.,1979, 776-783.
Liu, et al.,Inorg. Chem.,1999, 38(6), 1326-1335.
Margerstadt, et al.,Magn. Reason. Med.,1986, 3, 808.
Molema, et al.,Biochem. Pharmac.,1988, 55, 1939-1945.
Olson, et al.,Int. J. Cancer,1997, 73, 865-870.
O'Reilly, et al.,Cell,1994, 79, 315-328.
O'Reilly, et al.,Cell,1997, 88, 277-285.
Orlando, et al.,J. of Biological Chem.,1991, 266(29), 19543-19550.
Remington's Pharmaceutical Sciences, 17thEd.,Mack Publishing Co.,Easton, PA, 1985, p. 1418.
Runge, et al.,Radiology,1988, 166, 835.
Schaper, W., et al.,Academic Publ

Affiliated with

Also associated with

Rating

Vitronectin receptor antagonist pharmaceuticals does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vitronectin receptor antagonist pharmaceuticals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vitronectin receptor antagonist pharmaceuticals will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2800866